In preclinical studies, AT-587, Atea Pharmaceuticals’ lead oral candidate for treating hepatitis E, showed potent antiviral activity against multiple strains of the hepatitis…

Use of the experimental immune-modulating therapy CNP-104 in adults with primary biliary cholangitis (PBC) participating in a U.S. clinical trial led to greater reductions in markers…

Among children and adolescents with progressive familial intrahepatic cholestasis (PFIC), severe itch significantly affects sleep, overall perceptions of health, and the family’s quality of…